Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route

Infection and Immunity

Volumn 75, Issue 6, 2007, Pages 3043-3054

  Ravichandran, Easwaran ^a   Al Saleem, Fetweh H ^a   Ancharski, Denise M ^a   Elias, Mohammad D ^a   Singh, Ajay K ^a   Shamim, Mohammad ^a   Gong, Yujing ^a   Simpson, Lance L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALUMINUM POTASSIUM SULFATE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; CHITOSAN; IMMUNOLOGICAL ADJUVANT; TRIPLE VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOTULISM; CARBOXY TERMINAL SEQUENCE; HUMAN; HUMAN CELL; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL;

ANIMALS; ANTIBODY FORMATION; BACTERIAL VACCINES; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CELLS, CULTURED; DRUG ADMINISTRATION ROUTES; MICE; MUCOUS MEMBRANE; SEROTYPING;

EID: 34249879558     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01893-06     Document Type: Article

References (38)

1. Ahsan, C. R., G. Hajnoczky, A. B. Maksymowych, and L. L. Simpson. 2005. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 315:1028-1035.
2. Alpar, H. O., J. E. Eyles, E. D. Williamson, and S. Somavarapu. 2001. Intranasal vaccination against plague, tetanus and diphtheria. Adv. Drug Deliv. Rev. 51:173-201.
3. Arnon, S. S., R. Schechler, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, K. Tonat, and Working Group on Civilian Biodefense. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
4. Bleck, T. P. 2000. Clostridium tetani, p. 2537-2543. In G. M. Mandell Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, New York, NY.
5. Byrne, M. P., T. J. Smith, V. A. Montgomery, and L. A. Smith. 1998. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66:4817-4822.
6. Byrne, M. P., and X. Smith. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
7. Chen, F., G. M. Kuziemko, P. Amersdorfer, C. Wong, J. D. Marks, and R. C. Stevens. 1997. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect. Immun. 65:1626-1630.
8. Constantinides, P. P., J. Han, and S. S. Davis. 2006. Advances in the use of tocols as drug delivery vehicles. Pharm. Res. 23:243-255.
9. DasGupta, B. R., and V. Sathyamoorthy. 1984. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 22:415-424.
10. Fairweather, N. F., V. A. Lyness, and D. J. Maskell. 1987. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55:2541-2545.
11. Finegold, S. M. 1998. Tetanus, p. 693-722. In L. H. Collier, A. Balows, and M. Sussman (ed.), Bailey and Scott's diagnostic microbiology, 9th ed. Arnold, London, United Kingdom.
12. Hatheway, C. L. 1995. Botulism: the present status of the disease. Curr. Top. Microbiol. Immunol. 195:55-75.
13. Helting, T. B., and H. H. Nau. 1984. Analysis of the immune response to papain digestion products of tetanus toxin. Acta Path Microbiol. Immunol. Scan 92:59-63.
14. Johnson, E. A., and M. C. Goodnough. 1998. Botulism, p. 723-741 In L. H. Collier, A. Balows, and M. Sussman (ed.), Microbiology and microbial infections, 9th ed. Arnold, London, United Kingdom.
15. Kiyatkin, N., A. B. Maksymowych, and L. L. Simpson. 1997. Induction of immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65:4586-4591.
16. Kobayashi, R., T. Kohda, K. Kataoka, H. Ihara, S. Kozaki, D. W. Pascual, H. F. Staats, H. Kiyono, J. R. McGhee, and K. Fujihashi. 2005. A novel neurotoxoid vaccine prevents mucosal botulism. J. Immunol. 174:2190-2195.
17. Lacy, D. B., and R. C. Stevens. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898-902.
18. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
19. Maddaloni, M., H. F. Staats, D. Mierzejewska, T. Hoyt, A. Robinson, G. Callis. S. Kozaki, H. Kiyono, J. R. McGhee, K. Fujihashi, and D. W. Pascual. 2006. Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin a. J. Immunol. 177:5524-5532.
20. Makoff, A. J., S. P. Ballantine, A. E. Smallwood, and N. F. Fairweather. 1989. Expression of tetanus toxin fragment C in E. coli: its purification and potential use as a vaccine. Bio/Technology 7:1043-1046.
21. Maksymowych, A. B., M. Reinhard, C. J. Malizio, M. C. Goodnough, E. A. Johnson, and L. L. Simpson. 1999. Pure botulinum toxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect. Immun. 67:4708-4712.
22. Maksymowych, A. B., and L. L. Simpson. 1998. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem. 273:21950-21957.
23. Maksymowych, A. B., and L. L. Simpson. 2004. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 310:633-641.
24. Mitragotri, S. 2005. Immunization without needles. Nat. Rev. Immunol. 5:905-916.
25. Mu, L., and S. S. Feng. 2002. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (taxol). J. Control. Release 80:129-144.
26. Niemann, H. 1992. Clostridial neurotoxins - proposal of a common nomenclature. Toxicon 30:223-225.
27. Park, J. B., and L. L. Simpson. 2003. Inhalational poisoning by botulism toxin and inhalation vaccination with its heavy-chain component. Infect. Immun. 71:1147-1154.
28. Pellizzari, R., O. Rossetto, G. Schiavo, and C. Montecucco. 1999. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:259-268.
29. Ravichandran, E., Y. Gong, F. H. AI Saleem, D. M. Ancharski, S. G. Joshi, and L. L. Simpson. 2006. An initial assessment of the systemic pharmaco-kinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 318:1343-1351.
30. Sakaguchi, G. 1982. Clostridium botulinum toxins. Pharmacol. Ther. 19:165-194.
31. Schiavo, G., M. Matteoli, and C. Montecucco. 2000. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80:717-766.
32. Simpson, L. L. 2004. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44:167-193.
33. Simpson, L. L., A. B. Maksymowych, and S. Hao. 2001. The role of zinc binding in the biological activity of botulinum toxin. J. Biol. Chem. 276:27034-27041.
34. Simpson, L. L., J. J. Schmidt, and J. L. Middlebrook. 1988. Isolation and characterization of the botulinum neurotoxins. Methods Enzymol. 165:76-85.
35. Smith, T. J., J. Lou, I. N. Geren, C. M. Forsyth, R. Tsai, S. L. LaPorte, W. H. Tepp, M. Bradshaw, E. A. Johnson, L. A. Smith, and J. D. Marks. 2005. Sequence variation with botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73:5450-5457.
36. Somavarapu, S., S. Pandit, G. Gradassi, M. Bandera, E. Ravichandran, and H. O. Alpar. 2005. Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles. Int. J. Pharm. 298:344-347.
37. Swaminathan, S., and S. Eswaramoorthy. 2000. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693-699.
38. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from Polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.